CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

NDA 021995/S-013

Trade Name: **JANUVIA**

Generic Name: **Sitagliptin**

Sponsor: **Merck & Co., Inc.**

Approval Date: 12/28/2009

Indications: JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 021995/S-013

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	**X**
Other Action Letters	**X**
Labeling	**X**
Summary Review	
Officer/Employee List	
Office Director Memo	
Cross Discipline Team Leader Review	
Medical Review(s)	**X**
Chemistry Review(s)	
Environmental Assessment	
Pharmacology Review(s)	**X**
Statistical Review(s)	
Microbiology Review(s)	
Clinical Pharmacology/Biopharmaceutics Review(s)	
Risk Assessment and Risk Mitigation Review(s)	**X**
Proprietary Name Review(s)	
Other Review(s)	**X**
Administrative/Correspondence Document(s)	**X**

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

NDA 021995/S-013

APPROVAL LETTER

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021995/S-013 **SUPPLEMENT APPROVAL**

Merck & Co., Inc.
Attention: Richard J. Swanson, Ph.D.
Director, Regulatory Affairs
P.O. Box 1000, UG2C-50
North Wales, PA 19454-1099

Dear Dr. Swanson:

Please refer to your supplemental new drug application (S-013) dated and received March 5, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Januvia (sitagliptin) tablets.

We also refer to your supplemental new drug application (b) (4) dated and received November 13, 2009. Your submission of November 13, 2009, also constitutes a complete response to our October 16, 2009, action letter for supplemental application S-013.

In addition, we acknowledge receipt of your submissions dated December 3 and 9, 2009.

SAFETY LABELING CHANGES

Our letter dated October 16, 2009, notified you, under section 505(o)(4) of the FDCA, of new safety information that needs to be included in the labeling for Januvia (sitagliptin) tablets. This information pertains to the risk of acute pancreatitis, including necrotizing pancreatitis, with the use of Januvia (sitagliptin).

In response to the safety labeling change requirement outlined in our October 16, 2009, action letter, S-013 (b) (4) propose the addition of information regarding pancreatitis in the Highlights of Prescribing Information section, subsection Important Limitations of Use and subsection Warnings and Precautions, as well as in the corresponding subsections of the Full Prescribing Information section of the Package Insert. The agreed-upon changes to the language included in our October 16, 2009, letter are as follows (additions are noted by underline and deletion are noted by ~~strikethrough~~):

1. In the section Highlights of Prescribing Information, sub-section Indications and Usage, Important Limitations of Use, the following has been added:

JANUVIA has not been studied in patients with a history of pancreatitis. (b) (4) **(1.** (b) (4) **5.1).**

2. In the section Highlights of Prescribing Information, sub-section Warnings and Precautions, the following has been added:

   (b) (4) **There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. If pancreatitis is suspected, promptly discontinue JANUVIA.** (b) (4) **(5.1).**

3. In the section Full Prescribing Information, sub-section 1.2 Important Limitations of Use, the following has been added:

   (b) (4) **JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA.** ***[See Warnings and Precautions (5.1).]*** (b) (4)

4. In the section Full Prescribing Information, sub-section 5. Warnings and Precautions, the following has been added:

   (b) (4) **There have been postmarketing reports of acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, in patients taking JANUVIA. After initiation of JANUVIA,** (b) (4) **patients should be observed carefully for signs and symptoms of pancreatitis** (b) (4) **. If pancreatitis is suspected, JANUVIA should promptly be discontinued and appropriate management should be initiated. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUVIA.** (b) (4)

Additional agreed upon changes to the package insert include:

5. Under Adverse Reactions, Postmarketing Experience (6.2), the following has been added:

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.